5S ribosomal RNA pseudogene 133 (RNA5SP133)

5S ribosomal RNA pseudogene 133 (RNA5SP133) is classified as a processed pseudogene of the 5S ribosomal RNA gene family. Pseudogenes are genetic elements that resemble functional gene counterparts but have lost their ability to encode functional products due to mutations. They typically arise from either duplication with loss of function (unprocessed/duplicated pseudogenes) or retrotransposition (processed pseudogenes, as is the case here), and are dispersed throughout the genome without maintaining sequence conservation or regulatory function necessary for normal gene expression[4][2][10]. Unlike its functional parent, 5S ribosomal RNA, which is an integral structural RNA in the ribosome responsible for ribosomal assembly and protein translation[1][3], RNA5SP133 lacks the capability to code for a productive RNA or protein. Most pseudogenes, including those related to ribosomal RNA, do not produce functional molecules and are not directly targeted by drugs or considered primary candidates for therapeutic intervention[4][2]. However, emerging research has shown that pseudogenes as a group may play roles in gene network regulation, particularly in cancers and other diseases, sometimes by acting as competitive endogenous RNAs or lncRNAs that can affect the expression of other genes[6]. For this specific pseudogene, there is no evidence for a disease role or clinical application. RNA5SP133 is therefore not considered a canonical drug target such as a receptor, enzyme, transporter, or signaling molecule, and its inclusion as a distinct "target" may be incorrect in therapeutic contexts[2][4].

Other names

RN5S133RNA5SP133RNA, 5S ribosomal pseudogene 133RNA, 5S ribosomal 133